Recently many therapeutic classes have emerged in advanced hormone receptor-positive
breast cancer, which is the leading cause of cancer death in women. In absence of visceral …

Indications of immunotherapy in oncology are continuously expanding, and unconventional
types of response have been observed with these new treatments. These include transient …

Pembrolizumab is a full-length human immunoglobulin G4 (IgG4) monoclonal antibody
directed against the immune checkpoint PD-1 to remove its binding with PD-L1 and thus to …

Background Paraneoplastic syndromes (PNS) are autoimmune disorders specifically
associated with cancer. There are few data on anti-PD-1 or anti-PD-L1 immunotherapy in …

Purpose Totally implantable venous access ports (TIVAP) have been widely used for many
years in the management of patients suffering from cancer. The implantation and long-term …

Development of high-throughput technologies helped to decipher tumor genomic
landscapes revealing actionable molecular alterations. We aimed to rank the level of …

Precision oncology is currently based on pairing molecularly targeted agents (MTA) to
predefined single driver genes or biomarkers. Each tumor harbors a combination of a large …

Abstract Background: Randomized clinical trials (RCTs) of anticancer drugs without active
comparators in patients who have exhausted standard of care treatment options are …

Immunotherapy by chimeric antigen receptor (CAR)-modified T-cells has shown
unprecedented clinical efficacy for hematological malignancies. Recently two CAR T-cell …

Abstract Background Palbociclib, a CDK4-6 inhibitor, combined with endocrine therapy (ET)
is a new standard of treatment for Hormone Receptor-positive Metastatic Breast Cancer. We …